Skip to main content
Novartis
language-selector-globe
Choose Location
  • International
  • Americas
  • Asia Pacific
  • Europe
  • Middle East & Africa
Global | English
Novartis Foundation | English
Argentina | Español
Brazil | Português
Canada | English
Canada | Français
Andean & CAC | Español
Colombia | Español
Mexico | Español
United States | English
Australia | English
Hong Kong S.A.R. | 繁體中文
India | English
Indonesia | English
Japan | 日本語
Korea | 한국어
Mainland China | 中文
Malaysia | English
Philippines | English
Singapore | English
Taiwan | 繁體中文
Thailand | ภาษาไทย
Albania | English
Albania | Shqip
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Bulgaria | Български
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hungary | Magyar
Ireland | English
Italy | Italiano
Latvia | Latvian
Lithuania | Lithuanian
Netherlands | Nederlands
Norway | Norsk
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Serbia | Srpski
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Türkiye | Türkçe
Ukraine | українська
United Kingdom | English
Egypt | English
Israel | עברית
Saudi Arabia | العربية
South Africa | English
language-selector-globe
Choose Location
International Americas Asia Pacific Europe Middle East & Africa
Albania | English
Albania | Shqip
Argentina | Español
Australia | English
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Brazil | Português
Bulgaria | Български
Canada | English
Canada | Français
Andean & CAC | Español
Colombia | Español
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Egypt | English
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hong Kong S.A.R. | 繁體中文
Hungary | Magyar
India | English
Indonesia | English
Ireland | English
Israel | עברית
Italy | Italiano
Japan | 日本語
Korea | 한국어
Latvia | Latvian
Lithuania | Lithuanian
Mainland China | 中文
Malaysia | English
Mexico | Español
Netherlands | Nederlands
Norway | Norsk
Global | English
Novartis Foundation | English
Philippines | English
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Saudi Arabia | العربية
Serbia | Srpski
Singapore | English
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
South Africa | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Taiwan | 繁體中文
Thailand | ภาษาไทย
Türkiye | Türkçe
Ukraine | українська
United Kingdom | English
United States | English
    • About 
      • Board of Directors 
        • Giovanni Caforio 
        • Simon Moroney 
        • Nancy C. Andrews 
        • Ton Buechner 
        • Patrice Bula 
        • Elizabeth (Liz) Doherty 
        • Bridgette Heller 
        • Frans van Houten 
        • Elizabeth McNally 
        • Ana de Pro Gonzalo 
        • Charles Swanton 
        • John D. Young 
        • Charlotte Pamer-Wieser 
      • Executive Committee 
        • Vasant (Vas) Narasimhan 
        • Shreeram Aradhye 
        • Victor Bulto 
        • Aharon (Ronny) Gal 
        • Karen L. Hale 
        • Patrick Horber 
        • Rob Kowalski 
        • Steffen Lang 
        • Fiona Marshall 
        • Mukul Mehta 
        • Lutz Hegemann 
        • Teresa Jose 
        • Michelle Weese 
      • Products 
      • Therapeutic areas 
        • Cardiovascular, renal and metabolic 
        • Immunology 
        • Neuroscience 
        • Oncology 
      • People and culture 
      • Inclusion 
        • Promoting inclusion 
        • Building belonging 
        • Parental leave 
        • Caring for the mental health and wellbeing of our people 
      • Novartis Gene Therapies 
      • Manufacturing 
      • Quality 
        • Novartis quality management system (QMS) 
        • Audit program and regulatory inspections 
        • Product and patient safety training 
        • Product recalls 
        • Third-party suppliers 
      • Awards and recognition 
      • 30 years of Novartis 
      Mother and daughter cuddling on a bed in a kids room

      About

      Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach 296 million people worldwide.

    • Patients and caregivers 
      • Novartis commitment to patients and caregivers 
      • Diseases 
      • Patient organization funding 
      • Patients perspectives stories 
      Adult daughter talking to her senior parents on a bench in a park

      Patients and caregivers

      Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting.

    • Healthcare professionals 
      • Medical congresses and events 
        • ASCO Annual Meeting 
          • ASCO 2023 
      • Products 
      • Novartis pipeline 
      • Managed Access Programs 
        • Zolgensma® Global Managed Access Program (gMAP) 
        • Managed Access patient privacy notice and consent templates 
      • Novartis external funding 
      • Healthcare professional resources by country 
      • Investigator-initiated trials / studies 
      • Novartis medical information 
        • Submit medical enquiry 
      • Payments to Healthcare Professionals 
      Doctor discussing illness with patient in an office

      Healthcare professionals

      Resources for physicians and other healthcare professionals including clinical trial recruiting, grant funding, congresses and country-level information.

    • Research and development 
      • Technology platforms 
      • Research disease areas 
        • Cardiovascular and metabolic disease research at Novartis 
        • Diseases of Aging and Regenerative medicine (DARe) 
        • DAx: exploratory disease research at Novartis 
        • Global Health disease area research at Novartis 
        • Immunology disease research at Novartis 
        • Neuroscience research at Novartis 
        • Oncology research at Novartis 
      • Novartis pipeline 
      • Research collaborations 
      • Collaborations 
      Close up on the hands of a laboratory technician wearing blue gloves preparing a sample with pipette

      Research & development

      Discover how Novartis turns breakthrough science into transformative, high-value treatments.
       

    • ESG 
      • Access 
        • Creating sustainable business models 
        • Value-based pricing 
        • Sub-Saharan Africa 
        • Donations 
        • Novartis access principles 
        • Novartis oncology access 
        • Patents and licensing 
      • Environmental sustainability 
        • Nature 
        • Climate 
      • Ethics, risk and compliance 
        • Ethical behavior 
        • Compliance 
        • Human rights 
        • Learning and engagement 
        • Integrated risk assurance 
      • Global health 
        • Pandemic preparedness 
        • Chagas disease 
        • Leprosy 
        • Malaria 
        • Sickle cell disease (SCD) 
        • Novartis Foundation 
      • Inclusion 
      • ESG index 
      • Reporting and transparency hub 
        • ESG rating performance 
        • Patient organization funding 
        • Payments to healthcare professionals 
        • Public policy 
        • Animal research 
      HCP wearing a medical coat pulling a cart bicycle in rural african village

      Environmental, social and governance

      Learn about our commitments to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards.

    • Investors 
      • Event calendar 
      • Financial data 
        • Novartis annual results 
        • Novartis quarterly results 
        • Novartis SEC filings 
        • Product sales 
        • Fixed-income securities 
        • Expected currency impact 
      • Share data and analysis 
        • Share monitor 
        • Dividend information 
        • Share ownership 
        • Share overview 
        • Return on investment calculator 
      • Shareholder information 
        • General Meetings 
        • American Depositary Receipts (ADR) 
        • Share buyback 
        • Frequently asked questions 
      • Company overview 
        • Corporate governance 
      • Reporting and transparency hub 
        • ESG rating performance 
        • Reporting archive 
        • Social Impact & Sustainability targets 
        • Publications order form 
      • ESG 
      Business woman working on her laptop in a bright atmosphere

      Investors

      Updates and resources for investors including financial information, disclosures, events, share price, ESG and reporting.

    • News 
      • Newsroom 
      • Media library  
      • Stories 
      • Subscribe 
      • Events 
      Overhead view of a meeting room with people in the foreground and screens in the background

      News

      Information for journalists including press releases, statements, stories, multimedia resources and more.

    • Careers 
      • Career search 
      • Our business functions 
        • Careers in research and development 
        • Careers in operations 
        • Careers in commercial and sales 
        • Careers in global functions 
      • Why Novartis 
      • Career hub 
        • Temporary contracts 
      • Early careers 
        • Graduates 
        • Students 
        • US Biomedical Research internship programs 
        • Community exploration and learning lab (CELL) 
      Three business people in a modern and bright meeting room

      Careers

      Novartis is hiring! Find open positions, learn more about our strategy and culture, and apply today.

    • Clinical trials 
    • Partnering 
    • Supplier portal 
    • Report side effects 
    • Contacts 
    Mother and son cuddling on a couch in front of a window

    Home

    Working together, we can reimagine medicine to improve and extend people’s lives.

LOU064

Rhapsido®
Immunology
Phase 3
2027
BTK inhibitor
Chronic spontaneous urticaria, pediatrics
Supplementary Indication
  • Print
  • PDF

Novartis

Working together
  • Patients and caregivers
  • Healthcare professionals
  • Researchers
  • Job seekers
  • Journalists
  • Investors
Topics
  • Q2 2026
  • 30 years of Novartis
  • Access
  • ESG
  • SpeakUp
Explore
  • Pipeline
  • Products
  • Clinical trials
  • Partnering
  • Events
Therapeutic areas
  • Cardiovascular, renal and metabolic
  • Immunology
  • Neuroscience
  • Oncology
Footer Bottom
© 2026 Novartis AG
  • Terms of use
  • Privacy
  • Cookie settings
  • Contacts
  • Locations
  • Site map
  • Open source
  • Web accessibility
Novartis Site Directory
This site is intended for a global audience